Key Highlights
- Paradigm Biopharmaceuticals Limited (ASX:PAR) reports that an independent analysis of its Phase 3 PARA_OA_012 study supports a potential rest-of-world trial of iPPS.
- The independent review found statistically significant results in favour of iPPS on the primary endpoint in the rest-of-world cohort, consistent with earlier internal analysis.
- The independent analysis found similar responses to iPPS and placebo in the United States, and the company says that requires further assessment.
- The Board’s funded proposal has not yet been presented to creditors, and further development depends on funding and the administration process.
Paradigm Biopharmaceuticals Limited (ASX:PAR) has released the results of an independent Phase 3 analysis of its PARA_OA_012 osteoarthritis study of iPPS. The analysis was prepared by TrialKey Pty Ltd, a Subsidiary of Pathkey.AI Limited, based on de-identified participant data. The announcement, dated 19 November 2026, describes the review as supporting a basis for assessing a rest-of-world trial, while stating that the outcome is not a conclusion that a future trial will succeed.
What the Independent Analysis Found
In the rest-of-world cohort, TrialKey’s exploratory analysis found statistically significant results favouring iPPS for weekly average daily pain at day 112, the primary endpoint, and for physical function and patient-reported overall improvement. The company says these findings are consistent with its earlier internal analysis, although the two reviews used different study populations and methods.
The company’s earlier internal analysis of 95 participants, 45 on iPPS and 50 on placebo, reported an adjusted treatment difference of minus 1.105 points on the 0 to 10 pain scale in favour of iPPS, with a 95% confidence interval of minus 1.733 to minus 0.476.
The US Result and Data Caveats
In the United States, iPPS and placebo groups showed similar responses. The review identified a higher proportion of scheduled injections recorded as not given in the US, along with gaps in pain records. Paradigm says treatment delivery, data completeness and site performance need further assessment, and that expectations and natural changes in symptoms may also play a role. None of these has been established as the cause.
The company notes that TrialKey’s report is interim, that its calculations need to be reconciled with the sponsor’s official analysis, and that missing data may affect interpretation. The independent analysis did not include a safety assessment, though the safety findings reviewed by the independent Data Safety Monitoring Board were consistent with prior iPPS studies.
Proposed Pathway and Administration
Paradigm says it plans to consult the US FDA on the PARA_OA_012 results and to consider a pathway for US development. The proposed focus is a rest-of-world trial built on the independent findings, with countries and sites assessed on their ability to recruit suitable participants and collect reliable data.
The Board’s proposal seeks a funded pathway combining clinical development, regulatory engagement, funding and restructuring. The company states that the proposal has not yet been presented to creditors for approval, and that further development remains subject to funding, the administration process and applicable approvals.
Looking Ahead
The key next steps are the creditor consideration of the Board’s proposal, the FDA consultation and any funding arrangements. Whether a rest-of-world trial proceeds will depend on those steps as well as on the reconciliation of the independent analysis with the official data.






Please wait processing your request...